GlassScriptPhysician profile
Michael P Gabris
NPI 1023005568
$8,190.18
in general payments reported to CMS, 2019-2025
46 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,617 · 2020: $709 · 2021: $985 · 2022: $1,625 · 2023: $1,932 · 2024: $1,022 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,954 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.22 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,339.48 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,267.88 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $1,078.35 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $640.74 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $404.25 | 2019-2024 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $342.90 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $334.01 | 2019-2024 | Farxiga, Brilinta |
| Sanofi-Aventis U.S. LLC | $317.04 | 2019-2024 | |
| Amarin Pharma, INC. | $308.80 | 2019-2021 | |
| Chiesi USA, INC. | $300.00 | 2025 | Juxtapid |
| Pfizer INC. | $249.57 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.92 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $133.41 | 2019-2024 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $131.41 | 2019-2022 | |
| Biotronik INC. | $124.92 | 2019-2020 |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gabris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.